anoth stock picker year
undemand valuat remain select
follow recent initi coverag remain posit
fundament brand-focus pharma see repeat value-
orient name like outperform broader sector re-rat unlik
overal top bottom-lin growth us major in-lin histor averag
view beat rais seem unlik limit clinic data catalyst outsid
challeng handicap/navig immuno-oncolog readout compel new
product launch drive broader sentiment shift prefer momentum name
valu stock premium-pr stock binari risk
compani us gener exposur teva ahead
manag meet report also includ list question compani
 like acceler post-tax reform
expect impact us tax reform modest posit us major given
neutral slight reduct tax rate improv access ex-u cash ex-u
tax domicil spec pharma mostli us sale could see upward pressur
anti-bas eros provis similar last tax repatri expect us
major pharma access ex-u cash could spur uptick biopharma
consolid think acquisit compani could face patent
and/or biosimilar cliff view bolt-on mid-siz deal
like occur mega deal
oncolog clinic readout front-lin lung cancer close watch includ
bmi mrk possibl interim mid
competitor roch impow program readout given similar mechan
unclear differenti target agent forecast
competit front-lin market includ backbon agent either
dose combin chemotherapi sequenti chemo induct
autoimmun market cautiou lli taltz maintain launch
momentum psoriasi due new competitor rheumatoid arthriti expect
lli baricitinib ultim gain approv mid await data select-
diabet expect focu space novo nordisk
inject semaglutid diabet revers lli recent share gain phase data
novo oral semaglutid lli abil demonstr superior cv benefit
cardiovascular outcom trial rewind top-line late
top pick agn
top pick view possess strong leadership posit
growth market trade discount impli growth qualiti asset mix
includ under-appreci immuno-oncolog leadership still io
immuno-oncolog game despit delay hybrid spec/consumer/major
aesthet momentum significantli under-valued pharma busi pipelin
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price
object basis/risk page
valuat head
stock picker market meaning price dispers
tax reform resolut key pent-up demand
sort winner loser us tax reform
us drug price less step-chang
clinic read-out
bmy/mrk stake high front-lin lung io read-out
mrk/bmi keytruda inci ido inhibitor melanoma
lly- rewind studi diabet
oral cgrp clinic readout migrain
abicipar phase top-line wet-amd
abbv- rova-t littl differenti competit
focu upadacitinib vs humira ra
new product launch
verzenio vs
gener copaxon wildcard advair restasi biosimilar
focu
question manag
focu
question manag
focu
question manag
focu
question manag
focu
question manag
focu
question manag
focu
question manag
focu
question manag
focu
question manag
focu
question manag
valuat head
stock picker market meaning price dispers
outperform much us major pharma group
under-perform market subject pe multipl de-rat past
two year believ pullback valuat larg attribut
follow risk biosimilar increas fda approv fda guidanc
interchang us drug price pressur real pressur commerci side
pbm pharmaci benefit manag consolid theoret concern
chang govern program pharmaceut sector stock
picker market drg pharmaceut index compris
pharmaceut stock heavili skew five us major market cap weight
saw price perform gener in-lin market earn
season overal under-perform broader market versu
total perform coverag group mix three
compani outperform market five teva
meaning under-perform market
stock perform within group
hand compani pharma coverag group meaning under-perform
market due underwhelm pipelin updat unfavor
patent gener regulatori surpris includ patent invalid agn restasi
mnk inomax first gener approv teva copaxon us
gener price pressur hit teva particularli hard continu drag mnk
within coverag univers coupl larg mid-cap name
perform except well beat group market healthi margin
out-performance compani larg driven favor patent
settlement significantli reduc risk earli gener competit
compani top profit contributor jazz xyrem abbv us humira posit
clinic regulatori updat pipelin product includ abbv next-gener
immunolog pipelin venclexta jazz sleep vyxeo secondari
tabl price perform coverag univers
chart price perform coverag univers
us major fundament unchang ep revis mainli spec pharma
except ep compound-annual-growth-rate consensu estim either upwardli
revis rel steadi concern around us drug price
overdon strong new product cycl io taltz hand revis
uniformli downward across spec pharma coverag exhibit agn ep
compound-annual-growth-rate estim nearli cut half due restasi patent/gener
headwind least neg impact compani rare/orphan
drug portfolio gener insul payer competitor pressur
exhibit consensu ep compound-annual-growth-rate variou time point
broader sector re-rat peak valuat unlik
view us major pharma sector look attract valu trade
pe discount rel high-singl digit ep growth
see better valu certain name oppos group re-rat valuat drg
index look compel averag view tough comp
given pe multipl period inflat us drug price view
appear replic rel longer term comparison us major
trade modest discount drg index compar help also
includ compani vrx employ vastli differ busi model
us major pharma look metric includ dcf
us major trade discount pe impli dcf
slight discount rel pe impli ep compound-annual-growth-rate regress
analysi summari believ us major pharma appear modestli cheap across
multipl valuat analys remain select stock pick given catalyst
outlook
believ three factor limit broader pharma group pe re-rat histor
price insensit immunolog market increasingli becom crowd
multipl me-too option late-stag earli market shorter product life cycl
viabil biosimilar ignor termin valu assumpt gener
reflect neg termin growth rate associ key biolog franchis us price
less tailwind us gross net price dynam continu worsen accord
analysi bofaml equiti quant strategi team rel weight pharma
hold larg cap activ manag remain low level versu market
chart histor ntm price-to-earnings drg index pharma rel
tax reform resolut key pent-up
sort winner loser us tax reform
believ impact us tax reform modestli posit us major given
neutral slight reduct tax rate improv access ex-u cash ex-u
tax domicil spec pharma mostli us sale could see upward pressur
anti-bas eros provis believ analysi tax reform pharma compani
complex transfer price agreement tax plan strategi best
direct current pharma tax rate alreadi low suggest limit upsid
potenti lower us rate anti-bas eros provis could
neg impact compani ultra-low rate us major pharma believ
biggest posit like move territori tax system would free
access futur foreign earn ex-u cash long competit
disadvantag versu ex-u pharma provis summar exhibit
exhibit provis us tax reform implic major specialti pharma
cut effect
one-tim tax liquid asset illiquid asset
move territori system us tax foreign profit except
minimum tax thereaft certain deduct payment
foreign corp gener exclud cog
minimum tax global intang low tax incom gilti
neutral posit
modest neg
competit asset
deduct limit us ebitda ebit neutral modest neg neg
bofa merril lynch global research hous way mean committe
us major tax rate alreadi low focu repatri
tax rate compar prior us statutori rate suggest compani
overli burden high us tax rate view enabl
transfer price strategi shift profit away us toward
foreign tax jurisdict lower rate given limit disclosur around tax plan
complex multin imposs forecast neg impact anti-bas
eros provis although compani anticip effect rate
posit benefit effect non-gaap tax rate other expect neutral
impact balanc think access larg ex-u cash hoard total
favor cost vs prior system could facilit effici capit deploy
wed expect direct
spec pharma focu outlier ultra-low rate
spec pharma coverag group enjoy ex-u tax domicil averag non-
effect tax rate believ low rate also enabl
transfer price strategi reduc us profit royalti payment ip us
subsidiari foreign parent disproportion high us debt compani
focu tax reform potenti implic anti-bas eros provis
includ net interest deduct limit compani like allergan pay
effect rate respect indic reform would neutral
slight neg tax outlay near-term believ opportun
off-set medium term tax reform may one-off implic tax invert
spec pharma higher taxat dividend us sharehold
reduct orphan drug tax credit howev actual expect tax reform
net posit rate magnitud benefit defin view
suggest pay higher us tax rate peer
 setup look similar expect boost post-reform
last us tax repatri holiday six larg cap us major repatri
lead step-up activ subsequ year chart base
preced follow repatri would anticip increas
activ ytd exclud singl larg ex-u deal
continu dividend growth low single-digit pay-out ratio near current
level buyer side expect investor focu remain given
growth challeng patent loss exclus financi capac
larger deal although see also candid given pend us humira
biosimilar cliff see bolt-on size deal like occur mega deal given
latter rare vocal willing attempt
chart capit return cash-onli
top six compani schering-plough
chart need vs capac addit
detail methodolog describ within sector tax reform report pg
repatri top six
 cash
capac incr mn firepow net debt/
ebitda exist cash
us drug price less step-chang
view us drug price remain area focu investor pharma
space especi pend introduct bisoimilar larger categori well
increas competit me-too brand number larger market like
immunolog present anticip real price impact come
commerci payer pbm pharmaci benefit manag negoti drug price
access commerci medicar part formulari three largest pbm
negoti pharma transact account us prescript pbm
leverag negoti price/access improv sinc pbm consolid earlier
us price expect modest tailwind go forward
price deflat norm europ post-launch believ investor gener
focus us drug price histor compon sale growth
analyz weighted-averag list-pric chang top us revenu
gener product compar ratio impli price discount calcul
latter subtract ratio report compani sale net sale im sale
 gross sale prior rebat discount three trend observ
list-pric growth last increas
averag impli discount/reb
averag categori analysi suggest uptick
discounts/reb appear driven therapeut categori face
payer pressur sever year respiratori diabet anti-lipid drug categori
believ polit scrutini drug price elect year
potenti concern stir pot ahead mid-term elect
translat drug compani cautiou take list-pric increas fear
neg public scrutini base us drug price trend feedback
compani manag gener assum low mid-single-digit price benefit
innov product flat neg net price benefit less differenti
product compet older product categori
chart histor discount growth list price top us drug
yoy growth wac list price
chart histor discount select therapeut area
gener sector challeng carri
us gener market subject above-averag price pressur
expect like persist near medium term two reason consolid
custom base top three group purchas organ make
gener purchas chart anticip harmon wbad/econdisc
purchas organ modest neg impact price larger
compani forecast price eros stabil near histor mid-singl
digit eros level believ gpo group purchas organ
room consolid due anti-trust concern spike fda gener
approv skew approv approv product categori pressur
legaci base busi mani supplier expect surg approv
persist agenc look justifi gener user fee proce work
fda commission gottlieb taken aggress stanc simplifi speed
gener drug approv order reduc overal healthcar expenditur
leadership agenc expand priorit polici expedit review
first three gener anda abbrevi new drug applic area
competit limit per dr gottlieb agenc promis reduc review time
prioriti drug averag month eight month agenc
also commit improv clariti around develop complex gener
copaxon cite specif exampl
gener payer consolid continu worsen
drug wholesal retail chain drug store began form gener drug
purchas consortium reduc drug acquisit cost chart chart
provid snapshot big share gener drug purchas
may newest chang gener purchas landscap esrx
econdisc buy group purchas partner wbad accord teva
three larg consortium account gener purchas
go forward believ key investor question
time consortium bid re-bid new econdisc/wbad rebid
undisclos portion book busi wbad fulli reflect
compani gener price eros guidanc consensu us gener project
chart share us gener purchas
chart bofaml estim share us gener purchas
script
clinic read-out
bmy/mrk stake high front-lin lung io read-out
lung cancer common cancer us non-smal cell lung cancer
nsclc account lung cancer case chemotherapi
standard therapi late-stag nsclc mani year immuno-oncolog io
agent becom new standard care set market segment
basi express level keytruda fda-approv io agent
either monotherapi express tumor patient full fda
approv combin alimta chemotherapi patient regardless
express fda acceler approv opdivo keytruda tecentriq
fda approv monotherapi expect size address market
shrink time io agent like approv use set
 could expand keytruda mono use lung
report result phase look expand
use keytruda monotherapi nsclc patient beyond approv indic
high expressor express patient goal
establish efficaci keytruda monotherapi patient express
threshold studi compar keytruda monotherapi
cycl max chemotherapi cycl max enrol
nsclc patient exhibit exhibit base estim preval think
roughli half express patient
recruit across asia africa europ america exclud us detail
statist plan unknown think multipl cutoff could analyz step
manner os overal surviv progression-fre surviv primari
secondari endpoint respect
factor posit outcom
difficult assess likelihood success trial given limit amount
data earlier studi lung market model assum probabl
success po express base studi outcom
keytruda chemo henc establish benefit monotherapi patient lower
threshold would upsid current forecast provid factor
posit outcom could significantli lower threshold
factor support posit outcom
keytruda monotherapi approv set although
think full read-through appropri
multipl competitor studi set oak
show trend improv efficaci orr os higher
express benefit shown cutoff see
trend lower cutoff level
data small single-arm studi show median os
express group higher
shown histor chemotherapi view
factor posit outcom
hand data orr/pf benefit
entir group driven larg express modest benefit
express exhibit may difficult show statist
signific effect size small
fail bmi studi use lower cutoff
difficult conclud drive factor behind neg
outcom exclud possibl efficaci set may
difficult show lower cutoff level
larg commerci potenti success best case scenario
think current keytruda monotherapi label address
elig nsclc patient lower could mean addit
 patient estim increment net sale potenti
us europ combin estim clearli present materi commerci
opportun catalyst expect readout
exhibit site enrol
squamou lung cancer
focal point investor outcom multipl nsclc studi
expect readout near term includ estimate readout
estimate readout studi compar keytruda
paclitaxel nab-paclitaxel abraxan paclitaxel/nab-paclitaxel patient
squamou nsclc squamou histolog found patient nsclc
primari endpoint os estim primari complet date
multipl option mani unknown
major setback last year studi compar opdivo
monotherapi chemotherapi fail show benefit patient express
focal point investor outcom
larg phase studi compar opdivo monotherapi opdivo yervoy
opdivo chemotherapi chemotherapi nsclc present
analysi expect studi
akin platform compris three studi exhibit
studi assess opdivo fix dose everi two week
opdivo yervoy opdivo yervoy chemotherapi
neg express studi compar opdivo yervoy opdivo
yervoy opdivo chemotherapi opdivo fix dose
chemotherapi part all-com studi assess
opdivo chemotherapi opdivo fix dose chemotherapi
co-primari endpoint progression-fre surviv overal surviv os
disclos much statist power alloc earlier opdivo lung
studi use either os alon os orr co-primari endpoint
os alpha vs orr alpha henc think alpha weight could given
toward os express non-express studi three
arm exhibit alpha split across two experiment arm three arm
two co-primari endpoint dilut effect alpha note
express studi significantli larger two studi within well
earlier lung studi exhibit disclos
option interim look top-line data could readout earli
cross issu partial mitig ex-u patient enrol
cross-ov effect refer consequ patient cross one
treatment arm therebi carri effect prior treatment
eg chemo subsequ therapi eg keytruda could alter benefit seen
compar arm henc present challeng io cancer trial disallow
cross-ov includ signific number ex-u trial site
antibodi yet approv therefor patient chemo arm
abl cross antibodi progress like lead
better separ os curv els equal nevertheless unknown
proport enrol patient come countri io agent approv
therapi
option
option
dose
dose
dose
discontinu due ae
discontinu due ae
wclc esmo esmo io reck et al nejm cohort
therapi
histori smoke former current
orr
orr
orr
orr
orr
orr
orr
orr
mystic may spell doom bmi
azn announc imfinzi imfinzi tremelimumab fail show statist
signific benefit chemotherapi express azn urg
investor wait os data note power alloc os vs
endpoint indic os acknowledg small alpha
alloc could result neg outcom note
certain nsclc studi deliv os benefit without benefit howev
highlight shown set could
indic os exhibit see addit analysi
certain nsclc studi show os benefit demonstr trend
benefit higher cut off exhibit await mystic final os data
confirm efficacy/safeti profil imfinzi tremelimumab nsclc
caution direct read-through mystic assign
probabl success opdivo express nsclc
yervoy assum probabl success
roch azn registration-en clinic studi
chemotherapi exhibit roch recent present detail
data impow trial tecentriq avastin chemo vs avastin chemo vs
tecentriq chemo triplet regimen reduc risk death overal
surviv hazard ratio os hr rel avastin chemo median os
vs seem less favor compar shown
keytruda alimta os hr roch os data still immatur caution
direct comparison interestingli doublet regimen compris
tecentiq chemo rel similar efficaci avastin chemo orr hr
os hr overal efficaci data encourag view
think regimen broadli use due high toxic importantli impow
result provid posit read-through roch tecentriq chemo doublet studi
read success could directli compet
keytruda alimta perceiv neg catalyst mrk/bmi
alreadi forecast competit chemo-combo market model roch chemo
combo studi impow key readout expect next
roch present detail data impow trial tecentriq avastin chemo vs
avastin chemo vs tecentriq chemo triplet regimen reduc risk death
overal surviv hazard ratio os hr rel avastin chemo
median os vs seem less favor compar
shown keytruda alimta os hr roch os data still immatur
caution direct comparison see interestingli doublet regimen
compris tecentiq chemo rel similar efficaci avastin chemo orr
hr os hr overal efficaci data encourag view
think regimen broadli use due high toxic importantli
impow result provid posit read-through roch tecentriq chemo doublet
studi read success could directli compet
keytruda alimta perceiv neg catalyst mrk/bmi
alreadi forecast competit chemo-combo market model
ct gov cut unknown
pt
os data
os os neg orr
os orr differ cutoff
os orr
os high os moder
express os orr express
os
os select orr
tge os os tge
os variou cutoff orr
os os orr
os data
studi compar keytruda placebo complet resect
high risk stage melanoma trial primari endpoint recurrence-fre surviv
rf comer posit patient secondari endpoint includ distant
metastasis-fre surviv dmf dmf posit patient os os
posit patient studi recruit patient estim primari
complet may bmi studi recent report posit
outcom demonstr superior opdivo monotherapi similar adjuv
melanoma set stage iiib/c iv specif opdivo reduc risk relaps
compar yervoy high-risk patient relaps free surviv hr exhibit
estim patient us may meet elig criteria fda
grant prioriti review expect approv februari
expect registration-en studi readout
exhibit registr studi melanoma
exhibit registr studi adjuv melanoma
disc due teae
discontinu due ae
discontinu due ae
mrk/bmi keytruda inci ido inhibitor melanoma
indoleamin ido enzym shown creat
immuno-suppress tumor microenviron modul activ variou
immun cell mrk studi keytruda epacadostat melanoma keynote-
first registration-en ido combin studi
expect read posit outcom may modestli posit
mrk keytruda signific presenc melanoma monotherapi
regimen could pose direct competit threat opdivo yervoy combin
expect gener benefit posit patient small singl arm
studi indic encourag clinic activ safeti exhibit
consid benign safeti profil key differenti ido inhibitor
recent initi studi opdivo ido inhibitor
melanoma studi current enrol estim read
separ note roch develop tripl combin compris
tecentriq antibodi zelboraf braf inhibitor cotel mek inhibitor
braf mutant melanoma immin competit threat earli data indic
lly- rewind studi diabet
trulic dulaglutid once-weekli inject human glucagon like peptid
approv reduc blood glucos level diabet forecast trulic
lli second largest sell drug estimate key investor
controversi trulic relat competit impact novo nordisk once-
weekli inject semaglutid approv decemb whether blunt
competit impact nvo product secur cardiovascular cv benefit
claim on-going rewind studi primari outcom first occurr
composit cv death non-fat myocardi infarct non-fatal stroke
secondari outcom includ compon primari composit cv outcom
composit clinic microvascular outcom compris retin renal diseas
hospit unstabl angina heart failur requir hospit urgent
heart failur visit all-caus mortal studi power detect hazard
ratio cv event indic non-inferior prudent base case
top-line data expect late
oral cgrp clinic readout migrain
develop two cgrp calcitonin gene-rel peptid agent treatment
migrain atogep phase prevent prophylaxi migrain
ubrogep phase acut treatment migrain expect
readout migrain affect approxim us adult
us popul suffer chronic migrain triptan
commonli prescrib class drug acut treatment migrain estim
market size appli brand price current gener prescript
volum howev approxim one-third patient refractori triptan
remain unmet need effect drug differ mechan
migrain prevent atogep offer potenti oral dose advantag rel
registration-stag cgrp antibodi expect enter market
investor oral cgrp agent need establish safe given concern
potenti drug-class effect liver toxic
ubrogep efficaci data long-term safeti studi
focus safeti ubrogep date allergan provid sever
updat regard incid magnitud liver enzym elev patient
enrol phase program blind basi far level liver enzym
elev studi drug placebo arm combin within rang normal
allergan updat provid comfort note follow limit
date blind toxic could skew patient drug-arm
patient receiv singl dose ubrogep allergan updat
reflect chronic dose believ ubrogep need establish strong safeti profil
competit lli lasmiditan novel brand agent tripan refractori
patient allergan long-term safeti studi read efficaci ubrogep
demonstr efficaci phase two-hour pain freedom phase co-
primari endpoint assum probabl success program risk-
adjust peak sale approv without liver monitor
ubrogep gener close peak sale view
atogep phase efficaci top-line
focus efficaci drug improv migrain free day
compar registration-stag cgrp antibodi approxim patient
achiev reduct migrain day cautiou given lack support
proof-of-concept data would assum efficaci drop-off rel antibodi
given presum lower bioavail oral agent safeti phase
week studi look daili treatment provid comfort around liver tox
issu believ regul equal interest long-term safeti
studi believ two year away readout base order-of-
entri disadvantag versu cgrp antibodi proven highli effect
believ atogep face high bar safeti efficaci current assign
zero sale contribut ahead proof-of-concept studi readout howev proven
efficaci cgrp antibodi without liver toxic atogep could
blockbust drug due eas oral dose
abicipar phase top-line wet-amd
develop abicipar treatment wet-ag relat macular gener
wet-amd interim top-line agn on-going phase expect readout
regn eylea current domin us market larg due
lower-burden dose regimen competitor dose eylea vs
dose lucenti avastin furthermor nv ahead develop
timelin nv alreadi announc phase interim top-line new drug
demonstr patient maintain quarterli
dose regimen investor abicipar commerci success spite
later-mov disadvantag drug need well toler secur label
us market grown first nine month forecast
peak abicipar sale believ bull case revenu could add
valuat abicipar abl success manag wet-amd
patient toler inflamm quarterli dose regimen key
controversi abicipar go phase three-fold durabl efficaci
untest phase studi abicipar one quarterli dose cycl compar
three quarterli dose cycl test phase ocular inflamm occur
phase subject allergan use formul on-going
phase studi agn trial design allow crossov
studi arm therebi set high bar aim achiev quarterli dose
patient
abbv- rova-t littl differenti competit
rova-t target sclc small market high unmet medic need
buy-out stemcentrix acquir rova-t antibodi drug
conjug antibodi combin drug develop small cell lung cancer
sclc neuroendocrin tumor rova-t compris delta-lik protein
specif monoclon antibodi dna damaging/cel kill drug linker
connect two biomark express sclc case henc rova-t
allow target deliveri drug cells/pati express sclc
aggress difficult-to-treat cancer new case report year
advanc program rova-t on-going triniti
studi third-lin sclc exhibit
subdu expect triniti studi readout
triniti registr enabl studi investig rova-t monotherapi third-lin
later stage sclc standard care avail open-label single-arm
studi enrol patient express orr os primari
endpoint durat respons clinic benefit rate orr stabl diseas
secondari endpoint express cutoff primari endpoint
think possibl benchmark trial could orr median os
os although think number much lower real world believ
meaning higher orr os could achiev high express
estim sclc pt line therapi base strong data
sub-group analysi patient show orr os rate median os
benefit howev less pronounc rel benchmark henc present risk
studi view recent announc six month delay studi readout
cite fda request includ durabl data compar
result opdivo yervoy combin shown encourag data
alreadi use physician per nccn guidelin model assum risk
adjust peak world-wide sale rova-t
exhibit cross trial comparison sclc studi
exhibit select rova-t studi sclc
rova-t high
four cycl nivo non random cohort random cohort
focu upadacitinib vs humira ra
upacacitinib daili oral avail select janu kinas inhibitor
late-stag clinic develop multipl autoimmun disord role
jak inhibit autoimmun diseas well understood also valid xeljanz
pfe inhibitor fda-approv treat moder sever ra sinc
sale xeljanz black box warn seriou infect
malign abbv strategi upadacitinib optim benefit-risk profil
inhibit upacacitinib rheumatoid arthriti ra regulatori
file plan near-term catalyst ra program
compar data placebo humira biolog standard care
everi two week inject select compar studi select-compar global
studi recruit patient inadequ respons background
methotrex american colleg rheumatolog acr respons clinic
remiss cr base diseas activ studi co-primari
endpoint studi expect readout separ phase program
lli baricitinib demonstr acr respons rate week vs
humira head-to-head studi similar increment improv observ
set like benchmark upadacitinib judg
data five six pivot studi list exhibit support regulatori file
plan launch current forecast risk-adjust
sale ra
exhibit abbv upadacitinib studi rheumatoid arthriti
select beyond inadequ respons biolog dmard
select inadequ respons conv ention dmard
select monotherapi inadequ respons
select compar upadacitinib humira adalumumab inadequ respond
select choic upadacitinib orencia abatacept conv ention dmard inadequ respond
new product launch
psoriasi rel common skin disord affect adult biolog
penetr rel low estim abbv humira anti-tnf agent
lead biolog drug set although competit increas tnf-
refractori set market lli taltz agent strong launch
sale ytd seen flatten prescript trend follow
launch tremfya agent chart expect psoriasi biolog market
competit note tremfya approv biolog agent
shown head-to-head superior humira recent abbv risankizumab
agent also demonstr superior humira studi expect
market entri late y/i basi expect taltz benefit
recent fda approv psoriat arthriti forecast in-lin
consensu forecast global taltz sale
chart total prescript next-gener biolog
chart new brand prescript next-gener biolog
verzenio vs
lli verzenio abemaciclib work inhibit cyclin depend kinas
enzym involv cell division/repl process dysregul
express found mani cancer cell shown particularli import
hormon receptor driven breast cancer common form diseas
new case septemb verzenio becam third fda approv
approv treat breast cancer follow pfe ibranc nv kiquali
verzenio current approv treat patient metastat hormon driven
hr bc breast cancer estim approv set could occur
base file
ibranc kisqali fda-approv mbc base
trial respect verzenio grant fda prioriti review
octob base data-to-d demonstr consist efficaci
profil across inhibitor discuss esmo
comment longer term follow verenzio would like show median
line inhibitor month
verzenio approv twice-daili bid continu dose ibranc kisqali
dose daili intermitt dose compris week week
exhibit lower risk neutropenia enabl use continu dose
allow sustain target inhibit whether would translat
reduc resist improv long-term efficaci remain seen
safeti verzenio differ approv result less bone
marrow suppress frequent sever diarrhea relat exhibit
fda-approv label verzenio list vte risk requir patient monitor
symptom thrombosi pulmonari embol uniqu verzenio although
note initi label ibranc also list pe risk base
data later remov risk trend revers paloma-
overal expect pfe ibranc remain prefer treatment
hormone-driven metastat breast cancer competitor drug fail differenti to-
date verzenio physician feedback indic continu dose slight
advantag need wait patient blood cell count recov
whether translat deeper respons remain unknown forecast verzenio
peak sale come us market market share
ex-u
exhibit fda label comparison inhibitor
qd qd
thrombosi
exhibit commonli report advers event metastat
neutropenia
anemia
leukopenia
increas alt
increas ast
diarrhea
neutropenia
anemia
leukopenia
june complet acquisit anacor focus small-
molecul therapeut deriv boron chemistri platform part
transact acquir right crisaborol approv decemb
trade name eucrisa topic treatment mild-to-moder atop
dermat also call eczema patient age two year older eucrisa non-
steroid topic inhibitor enzym although specif
mechan eucrisa well understood thought work inhibit
overact implic worsen sign symptom
atop dermat eucrisa first non-steroid topic monotherapi inhibitor
multipl oral inhibitor approv indic
daliresp copd otezla plaqu psoriasi
atop dermat also call eczema chronic condit character
inflamm itch condit typic appear earli childhood
thought caus combin genet immunolog environment
factor atop dermat affect approxim million children adult us
mild-to-moder form eucrisa approv treatment
prior tradit option topic oral steroid carri safeti risk
regn dupix antibodi approv sever popul
patient whose diseas inadequ control topic prescript therapi
therapi advis
launch eucrisa slower anticip sale annual
howev continu expect eucrisa reach peak sale
provid prescrib eucrisa repeat prescrib
approxim patient start treatment approxim half commerci
live unrestrict access requir one electron step-edit downplay
slow initi uptak note compani engag extens earli free sampl
program mani recent conclud model sale
vs bloomberg consensu peak sale
vyxeo combin two standard-of-car chemotherapi agent daunorubicin
daun cytarabin ara-c formul drug-deliveri liposom acquir
commerci right vyxeo acquisit may celat
pharmaceut celat develop vyxeo base hypothesi optim
dose ara-c daun synergist molar ratio liposom encapsul
may allow drug bypass membran transporter-bas resist mechan
histor limit exposur leukem cell chemo agent physician treat
secondari aml patient cur intent bridg patient bone marrow
transplant new treatment regimen offer better surviv benefit
standard care chemotherapi without sacrif toler safeti much
welcom physician patient secondari aml vyxeo fda approv
august treatment secondari aml expect european approv
late
believ vyxeo potenti new standard care secondari aml
follow three reason vyxeo improv median surviv month
standard care chemotherapi compar safeti profil standard
care vyxeo provid patient better chanc receiv stem cell
transplant see limit direct competit recent approv late-stag
pipelin agent either target differ sub-popul vyxeo
use add-on vyxeo
model forecast vyxeo sale us
deriv ex-u market compar bloomberg consensu forecast
base physician feedback believ vyxeo strong phase data could paradigm
shift allow greater use chemo secondari aml patient forecast
secondari aml patient us get vyxeo assumpt
includ us global popul patient vyxeo replac current
standard care secondari aml slow initi uptak reimburs
formulari get sort averag us price/pati base weight
profil popul upsid key develop primari aml
cgrp agent repres improv current standard care
current patient episod migrain em chronic migrain cm either
manag oral gener non-specif diseas analges
tricycl anticonvuls topiram physician specialist feedback indic
agent offer limit benefit migrain prophylaxi agent allergan botox also
use migrain prevent issu botox patient must get
inject per quarter treatment least half patient
receiv treatment respond therapi specialist indic botox
appear less effect new cgrp antibodi base data
allergan pre-empt studi measur reduct headache-fre day
specialist perceiv botox drug reduc intens patient headach
wherea cgrp agent demonstr increas migrain free day two
migrain free day adjust placebo specialist view cgrp
antibodi well toler may bode well class
teva compet crowd cgrp categori
fremanezumab otherwis known teva fully-human monoclon
antibodi target cgrp ligand prevent migrain octob teva
announc submiss bla biolog licens applic submiss frema
us fda estim action date could occur around follow
compani use prioriti review voucher applic support two
success pivot trial known em episod migrain cm chronic
migrain teva one four compani late-stag develop antibodi
modul either cgrp ligand receptor one key controversi around
cgrp stori whether agent establish meaning clinic
differenti becom multi-blockbust drug remain unclear
extent formulari restrict place given larg number potenti
patient elig expect expens therapi
tabl cgrp program prophylaxi migrain episod chronic
follow
quarterli monthli
twice daili
phase episod migrain readout clinic trial
chronic migrain moment
bofa merril lynch global research compani present press releas ct gov
none cgrp agent look appreci differenti
view efficaci profil cgrp agent report phase data
gener seem compar none manufactur develop cgrp agent
appear tout better efficaci base cross-trial comparison migrain
specialist tend look absolut respons rate drug although placebo
rate differ cross-trial comparison look
differ drug control chronic migrain set placebo rate
variabl differ baselin migrain day
differ late-stag program gener three late-stag agent saw
placebo adjust reduct monthli migrain day registration-stag
antibodi demonstr similar toler treatment-emerg advers event
rate rang discontinu rate dose
develop monthli subcutan dose teva may compani
offer monthli quarterli dose would expect quarterli dose appeal
physician drop-off efficaci teva product toward end
month might make monthli dose prefer subcutan dose like
prefer aldr intraven administ product least one specialist
comment iv less variabl mayb prefer start
treatment transit sq teva frema appear higher rate
inject viscou creat indur specialist dont expect
disadvantag frema market
payer like carri sway pace magnitud adopt
migrain potenti massiv market would expect payer enact strict
prior author protocol ensur correct patient get like
expens therapi rel botox oral gener botox typic cost medic
system per patient/year physician get singl treatment
acquisit cost physician specialist report headach specialist make
meaning profit prescrib botox fee buy/bil spread accord
allergan sale botox migrain around total botox franchis sale
annual basi howev note million
migrain patient us prevent therapi target popul
discontinu within one year given cgrp antibodi administ
chronic rel benign safeti profil expans market
increas treatment durat could also place addit strain payer
cgrp becom crowd space teva presum exist sale
review voucher expedit frema fda review expect frema
becom one first approv cgrp drug sometim along amgn
erenumab pdufa may expect third entrant pdufa
follow aldr bla file teva frema model sale
vs bloomberg consensu lilli galmab
model sale vs bloomberg consensu
teva previous peg total cgrp market opportun around
believ frema potenti multi-blockbust drug model
conserv peak frema sale impli around dollar
share use mid-point teva estim respect ip teva believ
patent estat broad coverag cgrp ligand receptor compani
recent file complaint us howev see potenti upsid
litig unlik imagin best-cas scenario could consist receiv low
austedo educ market key unlock valu
may teva complet acquisit
ev deal teva acquir late-stag drug candid call
austedo previous known deutetrabenazin austedo subsequ
approv us treatment chorea associ huntington diseas
april tardiv dyskinesia adult aug current phase
develop treatment tic associ tourett syndrom pediatr
patient refer austedo deuter version lundbeck xenazin
tetrabenazin approv chorea associ huntington
drug act inhibitor regul level dopamin brain
although precis mechan action understood thought inhibit
result less dopamin signal postsynapt neuron turn
caus fewer involuntari movement given austedo deuter certain
hydrogen atom replac deuterium last longer bodi henc provid
interest asset exact market size could challeng
austedo two approv indic address differ market lead indic
chorea abnorm involuntari movement associ huntington diseas
hd rare fatal neurodegen diseas caus death brain
cell time huntington affect approxim individu us
symptom chorea condit manag subset
neurologist focus movement disord refer lundbeck xenazin
gener us sale dkkm prior gener eros austedo
also approv treatment adult tardiv dyskinesia td
debilit neurolog disord involv repetit involuntari movement td
often emerg side effect common antipsychot estim affect
approxim individu us td patient gener manag
psychiatrist histor reluct prescrib treatment
side effect primari drug prescrib austedo second drug
approv indic us neurocrin ingrezza also
inhibitor believ imper teva educ
market benefit treat td
base discuss physician specialist believ teva drug
gener compar efficaci austedo trial higher placebo respons
although nbix ingrezza perceiv simpler dose regimen
requir frequent titrat ingrezza block box warn depress
suicid risk dont see differenti sinc teva box warn
pertain hd chorea popul ingrezza approv treat
tabl drug profil austedo ingrezza
td
td
titrat weekli per day
maximum twice
daili total daili dosag
initi dose daili
increas daili
td rec dose
hd rec dose
td daili
hd applic
chart cross trial comparison austedo ingrezza td
endpoint reduct aim larger reduct better
collabor help mitig risk/cost ts develop
septemb teva announc enter partnership
nuvelut pharma develop austedo treatment tourett syndrom
pediatr patient unit state tourett syndrom affect
children us character repetit involuntari movement
vocal tic per teva nuvelut fund conduct clinic develop
directli phase teva respons lead regulatori process
commerci follow fda approv teva agre pay nuvelut pre-
determin payment neurocrin also develop ingrezza tourett ped
adult
watch earli launch trend far consensu
teva report austedo sale although compani
highlight earli launch titrat pack script larg subsid
compani per teva manag austedo track line expect
patient drug encourag read-through
neurocrin sale ingrezza view austedo
promis asset forese meaning out-performance consensu given
avail viabl competitor histor reluct psychiatrist
see bulk td patient treat td forecast sale
vs consensu
gener copaxon wildcard advair
copaxon view risk addit copaxon gener approv
factor teva consensu number current one gener
version copaxon higher valu strength approv believ
argument regulatori barrier around formul establish gener
bioequival copaxon carri less weight two separ applic
proven equival activ ingredi move forward believ investor focu
mnta/nv alreadi secur approv gener version
lower strength pend full partial resolut manufactur relat issu
believ product could made avail anoth gener
approv would anticip teva forc renegoti pbm contract
like conced share price forecast impact second gener copaxon
worth lower teva sale major fall bottom
advair given size opportun focus first wave ab-
rate gener advair program name sandoz tad april fda action
date estim teva anda submiss expect late
thu potenti launch like multipl year away view
restasi follow octob patent invalid assum full
generic restasi restasi repres larg opportun ltm net sale
shape crowd gener market consid ten gener
manufactur includ bridg studi goal date file anda
referenc restasi although none receiv approv yet
neulasta neulasta annual ww us
larg market attract multipl biosimilar manufactur none far
success apotex/inta report fda accept applic
presum later receiv complet respons letter nv sandoz issu
juli plan resubmit follow complet addit pk
studi coheru issu june requir compani develop
valid higher sensit immunogen assay plan resubmit around
final myl/biocon receiv base manufactur defici issu
rais pk pkd clinic immunogen data base manag
commentari respons fda like alreadi submit
estimate end patent stay
mid june per management call
file plan
known anda filer
bridg studi goal date
buy thesi part base compani abil execut
broader immunolog strategi street underappreci strength humira
formul patent view combin patent litig timelin give
us confid us biosimilar optimist
commerci potenti next-gener immunolog agent
partial mitig humira revenu lost us biosimilar
signific negoti leverag biosimilar develop like lead
patent settlement push biosimilar launch beyond view
offer visibl investor potenti time develop next-
focu
view focu sever pipelin product
competitor product event includ valid abbvi next-gener
immunolog pipelin come select-compar head-to-head studi
look upadacitinib versu humira rheumatoid arthriti lli fda action date
product label olumi baricitinib could read-through term
agenc view low rate thromboembol event occur
jak inhibitor ra patient look detail clinic data
upadacitinib atop dermat risankizumab psoriasi medic event
biosimilar competit humira europ launch late
investor see first quarterli sale report earli would
anticip enter us humira patent settlement leverag
strength product formul patent
anytim possibl humira patent settlement
 upadacitnib ra data select compar studi
 risankizumab detail data present psoriasi
 rova-t sclc small cell lung cancer studi readout triniti
question manag
discuss humira trend psoriasi market durat therapi
neg impact introduct new effect agent probe-
new agent grow overal biolog psoriasi market
agent slow growth humira market segment
manag talk posit risankizumab behind
humira eventu look move agent upstream treatment
algorithm key autoimmun market discuss catalyst move newer
agent upstream includ head-to-head data versu humira role medic
guidelin key market segment
expect term speed uptak risankizumab psoriasi
discuss initi impact azn calquenc imbruvica mcl mantl
cell lymphoma outlook competit larger cll chronic
discuss real world imbruvica discontinu rate averag durat therapi
front-lin set
compani abl bolster mavyret commerci formulari posit
sinc compani last investor updat compani hcv sale target
still feasibl
allergan registration-stag esmya uterin fibroid either fail gain market
approv get restrict label durat liver test repres
materi upsid sale forecast
statu legal patent challeng next wave us humira biosimilar develop
sandoz boehring ingelheim could patent trial get schedul
eu biosimilar humira discuss percentag ex-u sale expos biosimilar
competit start
rate buy believ continu strong cash flow gener focu
sharehold return stabl grow dividend well signific share
buyback expens control potenti posit pipelin news could improv
sentiment time lead multipl expans pipelin portfolio
underappreci street believ posit outweigh high
exposur loss exclus rel pharma peer near term
focu
notabl pharma laggard stock perform brand gener
competitor threat key portfolio product saw develop advanc
expect investor focus clinic readout key pipelin program notabl
migrain program us regulatori updat esmya launch botox
competitor cosmet therapeut migrain indic corpor
restructur includ possibl split asset swap new cfo hire
 phase data atogep migrain prevent
 phase data ubrogep acut migrain
march may ema find safeti esmya uterin fibroid
 fda approv label esmya
 phase top-line abicipar wet-amd
question manag
provid updat liver toxic seen blind basi date
atogep ubrogep on-going clinic studi includ incid rate
medium durat exposur atogep prophylaxi studi
allergan believ critic clinic differenti novel acut
migrain treatment includ agn phase ubrogep lli lasmiditan
probe import demonstr efficaci pre-specifi patient
base payer feedback allergan anticip new anti-cgrp antibodi
forc step-through botox migrain prophylaxi
would payer give botox prefer formulari statu anti-cgrp antibodi
sinc prescrib train botox injector botox approv
prevent episod migrain
allergan learn anyth increment regard post-market safeti report
liver failur patient treat esmya europ
discuss progress allergan made expand coolsculpt prescrib base
sinc compani acquir zeltiq like catalyst drive
increas bodi sculpt prescrib base
discuss estim oper margin allergan aesthet busi
discuss statu allergan pilot commerci program aim increas
util aesthet medic product
compani discuss take paus deal discuss
area current portfolio area compani activ
look augment
compani think increas dividend lieu us tax reform
measur appli increment tax sharehold dividend invert
compani allergan
rate share neutral given hard handicap natur
studi assess opdivo opdivo yervoy opdivo chemotherapi front-
line lung cancer investor view binari risk move stock /-
extrem scenario think complet failur unlik
focu opdivo yervoy combin key bmi differenti
premium multipl limit earli clinic data detail statist
plan make difficult handicap outcom howev believ current
consensu forecast vs alreadi reflect
meaning expans key market lung follow melanoma renal cell
carcinoma think bmi earli mid-stag immuno-oncolog io pipelin offer
meaning opportun upsid program requir clinic valid
assign credit
focu
expect focu advanc compani immuno-oncolog portfolio
well competitor updat determin bmi posit key market
front-lin lung cancer view import year determin
breadth futur opdivo antibodi util well role yervoy
combin partner lung cancer set beyond bmi first-wav
io asset continu initi registr studi io includ
combin ido indoleamin inhibitor
provid increas visibl time strategi plan employ
treat broader group patient io last expect continu
subject takeout specul see us tax reform potenti catalyst
 interim readout studi
opdivo yervoy readout front-lin sclc
 competitor readout nsclc studi
question manag
talk confid around opdivo yervoy combin
show meaning benefit opdivo studi part
appropri efficaci threshold opdivo yervoy
estim use current follow
updat esmo
expect much address nsclc market could
shrink follow keytruda approv
management previous mention certain catalyst would impact
growth immuno-oncolog product latest thought
whether key io agent opdivo yervoy grow
comment stage tumor mutat burden tmb
biomark develop broadli applic may across tumor
talk earli uptak opdivo adjuv melanoma us
also quantifi like revenu impact yervoy also
approv set
discuss effort operation biopsi process nash clinic studi
ahead phase start
neutral believ compani difficult time achiev
multipl expans and/or beat street estim face numer
headwind diabet busi slower expect uptak new product
launch limit pipelin catalyst diabet front believ two
biggest headwind like come lli top two sell diabet product trulic
humalog face new competit nvo inject semaglutid
sanofi biosimilar version humalog respect new product launch front
cautiou lli two high profil launch product taltz psoriasi verzenio
breast cancer believ product risk fall short consensu expect
last cautiou lli upcom data expect verzenio
show meaning differenti pfe ibranc posit
expect olumi gain fda approv ra heighten safeti warn
focu
expect focu competit impact trulic novo glp-
franchis diabet whether lli trulic demonstr cardiovascular
superior placebo rewind cardiovascular outcom trial baricitinib us fda
action date label rheumatoid arthriti whether sanofi biosimilar humalog
caus competit disrupt lli humalog franchis
 competitor novo nordisk trial readout oral semaglutid
mid fda approv decis olumi baricitinib ra
late readout rewind trulic cardiovascular outcom trial
question manag
manag gain better visibl sanofi launch strategi biosimilar
humalog admelog competitor launch could impact net price
manag view key catalyst drive convers share
basal insulin product long believ take glp-
becom prefer first-lin inject treatment option
demonstr superior cardiovascular cv benefit rel placebo rewind
studi necessari trulic grow given cv data gener
talk anticip us formulari access galcanezumab
prevent chronic episod migrain
compani anticip payer enforc multipl step-edit oral gener
botox inject cgrp antibodi gain formulari access migrain
manag anticip payer adopt prefer formulari posit
anti-cgrp antibodi compani expect cgrp antibodi
allow formulari
discuss key factor need baricitinib success
launch rheumatoid arthriti pfizer competitor jak inhibitor xeljanz
import head-to-head data versu humira gain medic guidelin
recommend enabl long-term formulari accept baricitinib
pariti anti-tnf agent
discuss measur taken mitig occurr rapidli
progress osteoarthr phase studi broadli applic phase
tanezumab result oa chronic lower back pain market
discuss measur taken drive physician adopt verzenio
metastat breast cancer mitig high phase studi discontinu rate
fundament like merck highli diversifi biopharma franchis
domin posit immuno-oncolog io fast-grow class drug target
bodi inher abil attack cancer cancer treatment paradigm continu
shift toward io combin believ keytruda like maintain solid posit
backbon io therapi support establish posit key indic
on-going clinic trial highest amongst competitor although acknowledg
increas competit space especi lung cancer singl largest cancer
indic recent announc delay one lung trial readout
creat neg catalyst path competitor trial read first put
behind competitor month think risk price
current valuat summari believ offer favor mix attract
valuat sustain return cash sharehold dividend yield diversifi
revenu base substanti pipelin option driven keytruda
price object po base blend averag risk-adjust
discount cash flow dcf target price-to-earnings multipl believ dcf
assumpt reason given minim contribut new keytruda
indic yet valid late stage clinic studi erod
revenu base januvia/janumet zepati neg termin growth
multipl base regress analysi histor us major
pharma forward month price-to-earnings multipl forward compound-annual-growth-rate non-gaap
focu
expect focu advanc compani immuno-oncolog portfolio
well competitor updat determin mrk posit key market
front-lin lung cancer view import year determin breadth
futur keytruda antibodi util expect investor focu
mrk financi guidanc gaug competit impact zepati hcv
zostavax shingl extent net price pressur januvia franchis
diabet beyond near-term top-line growth issu expect investor
focus keytruda label expans studi includ readout nsclc
monotherapi low expressor squamou nsclc
adjuv melanoma us tax reform given mrk januvia patent cliff
expect investor focu potenti acquisit
readout keytruda epacadostat melanoma
 readout studi keytruda monotherapi
 readout studi keytruda chemotherapi
 readout studi keytruda monotherapi
question manag
factor influenc whether decid publicli disclos
interim data
confid around studi whether would abl
meaning increas address nsclc popul
big market adjuv melanoma us/ex-u
expect studi outcom
talk uptak keytruda alimta combin nsclc
recent month follow updat esmo
discuss strategi gain market access categori
prior read-out ertuglifozin cvot data import view cvot
data gain formulari access categori
us tax reform provid latest thought
manag publicli express bia toward bolt-on size deal whether
improv access substanti ex-u cash alter compani thought
pleas discuss key hypothesis-gener io combin studi readout
rate buy like orphan drug focu typic devoid
competit payer risk forecast mid-teen top bottom-lin growth
driven new product vyxeo unresolv patent
litig around largest franchis xyrem remain overhang believ
prospect favor final patent settlement outstand gener
challeng would expect settlement improv stock sentiment
focu
believ investor focu around mitig risk
associ jazz largest franchis xyrem patent settlement
outstand patent challeng advanc jazz xyrem life cycl
manag program vyxeo launch secondari aml acut myeloid leukemia
commerci perform xyrem potenti settlement associ
govern probe jazz charit co-pay assist foundat
 nda file wakix pitolis treatment cataplexi
 phase top-line parkinson
 potenti approv excess sleepi
late phase top-line lower sodium xyrem
anytim settlement four outstand xyrem gener challeng
question manag
discuss vyxeo launch secondari aml whether lack j-code
impedi uptak
discuss import investigator-sponsor clinic trial read-out
inform futur vyxeo develop strategi
comment vyxeo adopt real-world set particularli
patient get averag vial vyxeo treatment
consolid phase migrat out-pati set
comment manag decis take reserv cover
potenti monetari fine stem govern probe
compani donat organ street view lack
reserv sign manag confid wont need pay fine
discuss import mileston xyrem patent disput secondari
patent challeng estimate trial date may serv catalyst gate
factor settlement agreement
pleas discuss whether anticip meaning chang xyrem
narcolepsy/cataplexi manag care payer coverag
manag still believ wake promot command price
premium given avail numer gener wake promot
manag continu see mainli treatment option
patient refractori current option would compani envis one
two drug step-edit patient elig
manag view us tax reform provis limit net interest
deduct meaning factor alter compani appetit leverag
return metric deal
pleas discuss statu erwinaz manufactur output partner pbl
whether compani envis better posit meet market demand
even facil warn letter resolv
rate under-perform believ share remain depress
valuat due competitor overhang acthar inomax franchis
collect account oper profit pipelin program either
target nich market demonstr clinic efficaci gener busi
continu face headwind
focu
believ investor focu whether acthar recov
stagnant sale growth seen due increas payer pressur drop-off
prescript fulfil rate fda approv decis inomax gener
weigh stock key patent knock district court
fda feedback ani effort reactiv dormant nda
would ani reintroduc competit acth product market
februari earn report updat acthar
 phase interim data terlipressin progress kidney failur
hepatoren syndrom
 development updat corticotropin
phase readout niemann-pick diseas type
pend close scmp acquisit
anytim fda approv praxair inomax gener
competitor depom acthar nda undisclos condit
question manag
mnk updat compani increment learn
acthar reimburs prescript fulfil issu
rate limit step resolv acthar reimburs challeng
emerg
acthar indic see greatest demand product
indic biggest headwind growth
inomax compani modifi hospit contract strategi mitig
potenti impact praxair brand gener offer bigger discount
custom exchang long-term contract
cite exampl praxair launch gener version inomax canada
limit market share captur pleas discuss rel market size
inomax canada versu us market
manag expect us controlled-subst gener face similar
downward pressur year prior probe compani expect
final clariti around gener concerta earli
pleas discuss outlook stannsaporfin sever jaundic us launch
trajectori quickli expect hospit institut get comfort
safeti profil drug neonat patient
sucampo acquisit much valu assign
program given sucampo owe meaning post-approv mileston payment
product subject profit share
discuss outlook revenu tail sucampo amitiza royalti light
patent settlement allow gener entri time-frame teva
mnk top capit alloc prioriti
neutral see balanc invest posit neg like
prospect upsid number us copaxon remain sole-sourc
gener g-advair approv convers concern around
headwind myl us legaci gener base busi competitor approv key
gener product copaxon levo cautiou consensu
growth profil myl intern generic/otc busi enter first
report period wont benefit meda acquisit non-gaap
ep forecast manag guidanc question whether investor
reward compani non-gaap ep target appear deriv
focu
focu intern busi multipl major
 deal cautiou consensu first quarter without favor
 a-driven comp outcom gener wildcard event
littl visibl advair restasi potenti addit gener copaxon
mid estimate us fda action date gener advair g-advair
 us fda pdufa revefenacin
 estimate us fda action date g-restasi
anytim potenti approv competitor g-copaxon
question manag
confirm remain track us regulatori action gener
restasi gener advair mid-jun possibl earlier
mylan success acceler mid-jun g-advair fda action
date key variabl would enabl move action date
g-advair approv prepar suppli least half
g-advair relat conting consider program
mainli payabl upon regulatori approv mileston achiev sale
gener copaxon oper margin above/below corpor
averag product given profit share natco
file gener lantu non-interchang applic
data compani believ help fda get comfort
discuss anticip impact gpo consolid us gener drug
price probe whether manag expect wbad-econdisc claruson
drive materi price deceler
plan disclos quarterli perform portfolio product base
channel strategi brand rx over-the-counter gener rx
implement cost reduct sinc meda acquisit
manag believ room spend reduct
manag top capit alloc prioriti
buy rate view compani current valuat undemand
rel compani forecast non-gaap ep growth compound-annual-growth-rate
compar group mean upon expiri lyrica pain
expect return top-line growth driven compani key innov brand
face modest near-term patent cliff sale
encourag recent event strengthen pfe market leadership key
innov notabl ibranc breast cancer xeljanz rheumatoid arthriti
offer attract view sustain dividend yield on-going
strateg review consum busi state intent engag post us
tax reform outcom could enhanc sharehold valu
focu
primarili focus pfe progress launch product eucrisa
xtandi potenti sale compani consum busi bloomberg report
multipl bid rang potenti follow passag us tax
reform view potenti sale consum unit would make sens
would beef compani financi capac acquir innov medicin
compani express desir past scale innov pharma
essenti health divis innov unit face number patent loss
exclus period openli discuss engag
larger scale resolut us tax reform remov impedi
suggest us compani could activ deal front
 regulatori approv xeljanz ulcer coliti
 top-line data bavencio ovarian javelin
 regulatori approv xtandi non-mcrpc
end updat strateg review consum busi
question manag
think versu form capit deploy
cash repatri immin still potenti appetit
discuss rel prioriti compani think
bolster innov health portfolio pipelin versu expand
far along evalu consum busi
import tax implic sharehold potenti transact
discuss whether xtandi util normal given return
manag latest thought ibranc breast cancer growth
potenti recent introduct lli verzenio nvss kisqali
pfizer surpris efficaci talazoparib in-lin parp
inhibitor germlin brca posit breast cancer embraca result alter
compani view tala potenc would allow drug differenti
eucrisa atop dermat discuss investor abl see
true reflect demand-driven growth report sale longer
dampen extens sampl effort
discuss measur taken mitig occurr rapidli
progress oa phase studi broadli applic phase
tanezumab result oa chronic lower back pain market
late mover number import market discuss pfizer
appetit compet cost market late-mov
manag provid detail compani
resolv legaci hospira steril inject shortag confid
compani issu resolv end
under-perform teva bearish near medium term
outlook teva three reason us gener sector trend like remain
challeng teva major new gener product come market
teva gener advair file schedul submiss late
risk addit copaxon gener approv factor consensu
key new spec brand like see slow uptak under-perform consensu expect
migrain austedo movement disord face formid
competit respect end market believ teva ultim
abl pay substanti debt load capit structur believ
process like slow teva histor oper rel lean
focu
expect focu progress toward teva propos
cost reduct revenu impact guidanc occur result
manufactur facil closur reduct sell market spend
refinanc near-term debt oblig potenti addit gener copaxon
approv launch progress migrain austedo
earli estimate decis disput work capit actavi arbitr
mid -fda action date fremanezumab migrain prevent
 ph top-line fasinumab osteoarthr knee
question manag
discuss anticip impact gpo consolid us gener drug
price probe whether manag expect wbad-econdisc claruson
drive materi price deceler
discuss date certain gener launch us market
discuss disconnect copaxon im data teva anticip
market share assum new competitor probe- assert
roughli one-third market captur im data
mani competitor teva anticip market teva
launch fremanezumab probe time next updat teva patent
infring suit launch
teva plan posit fremanezumab once-monthli once-
quarterli dose product offer migrain market teva view
import featur frema differenti versu competitor cgrp product
discuss specif area teva sell market effort
neg impact compani recent announc cost cut plan
manag view appropri long-run oper profit margin
discuss teva specif prioriti follow compani cost cut plan
teva focus commerci resourc earli launch
austedo movement disord probe compani focus neurologist
movement disord specialist neurologist psychiatrist
austedo teva anticip phase free titrat script
transit revenu gener prescript
price object po base blend valuat risk-adjust dcf
target price-to-earnings multipl non-gaap ep estim
target multipl in-lin peer averag assum wacc
termin growth rate believ dcf assumpt reason
minim contribut pipelin valid late-stag
clinic studi histor trade discount peer price-to-earnings
owe humira biosimilar risk multipl expand last month
believ warrant base humira settlement pipelin readout risk
earlier-than-anticip launch humira biosimilar us clinic pipelin
price object base blend averag dcf ev/ebitda
multipl price-to-earnings multipl rel us major brand
specialti pharma expect trade premium ev/ebitda multipl
reflect sale mix increasingli skew higher multipl aesthet franchis
generic sever pharma product expect price-to-earnings multipl
start converg price-to-earnings multipl us major pharma
compar ep growth time-to-catalyst shorten dcf analysi base
view conserv assumpt includ restasi us gener
competit rel modest contribut recent approv product
assign zero valu specul phase program minim cost
cut even though manag team explor area make compani
effici wacc termin growth
downsid risk po us drug price pressur older product
franchis estim contribut sale new competit key
brand may erod allergan market share current forecast failur
clinic pipelin program could neg read-through sentiment
deal perceiv valu destruct
upsid risk po delay approv compet gener drug
better- than-expect sale growth new launch
po base blend averag risk-adjust discount cash
flow dcf price-to-earnings multipl believ dcf base reason
assumpt compris minim contribut new opdivo/yervoy indic
valid late-stag clinic studi eliqui continu grow
prefer novel oral anticoagul gradual contribut pipelin
asset lead sale roughli line annual
spend dcf assum wacc termin growth rate vs
averag us major pharma peer price-to-earnings multipl reflect higher-than-averag
non-gaap ep growth vs averag us major pharma peer base
regress analysi histor us major pharma peer forward month price-to-earnings
multipl forward ep compound-annual-growth-rate
downsid risk po complet failur front-lin lung cancer studi
although unlik view opdivo yervoy combin
show compar efficaci chemo base combin
high toxic neg result rel earli stage io pipelin slower-
than-anticip growth eliqui opdivo yervoy combin show compar
better efficaci benign toxic opdivo monotherapi
show efficaci express
compani
price object po base blend averag discount
cash flow dcf target multipl appli ep po impli
stock trade roughli ep base regress analysi
us major pharma compani forward price-to-earnings three-year ep compound-annual-growth-rate dcf assum
wacc termin growth upsid risk po better-than-
anticip margin expans on-going cost-cut program verzenio
show meaning clinic differenti result signific uptak downsid
risk po slower growth trulic rapid biosimilar eros
humalog franchis slower growth new product launch
price object po base blend averag discount cash
flow dcf price-to-earnings multipl ev/ebitda multipl multipl
line brand specialti pharma peer compar weaker growth
trajectori view multipl floor valuat stock assum
wacc termin growth rate dcf believ dcf analysi
base reason assumpt includ continu slow growth
xyrem loss xyrem exclus one-third convers next-
gener formul success launch vyxeo approv
indic product gener peak sale without label
downsid risk po slower-than-expect sale growth vyxeo
miss window j-code launch slower-than-expect sale
growth xyrem includ failur gain approv next-gener formul
xyrem xyrem loss exclus prior
upsid risk po greater-than-expect sale growth vyxeo jzp-
launch less-than-expect gener eros xyrem eg due difficulti set
gener rem futur busi develop transact core
element compani strategi
price object po base multipl ev/ebitda
compar current multipl specialti brand
gener peer averag use ebitda multipl forecast
growth trajectori gener peer given variou uncertainti
around key brand growth driver prospect acthar competitor
updat believ dcf analysi appropri valuat methodolog
ebitda multipl base follow assumpt declin
acthar sale driven payer pressur near term competit entri
generic inomax margin contribut pipelin program
given terlipressin inhal xenon ga clinic valid phase
phase studi
upsid risk po fda approv acthar competitor program
fda approv inomax gener better-than-expect recoveri acthar sale
growth spite price scrutini payer pressur
downsid risk po greater-than-expect pressur payer
competitor acthar gener eros inomax gener busi
price object po base blend averag risk-adjust
discount cash flow dcf target price-to-earnings multipl appli ep
dcf assum wacc termin growth rate believ dcf
assumpt reason given minim contribut new keytruda
indic yet valid late-stag clinic studi erod
revenu base januvia/janumet zepati neg termin growth
target price-to-earnings multipl base regress analysi histor us major
pharma forward price-to-earnings multipl three-year forward compound-annual-growth-rate
risk failur keytruda chemotherapi studi front-lin lung cancer
competitor report result look substanti better
shown keytruda chemotherapi earlier studi
higher-than-anticip price pressur diabet franchis neg result
late-stag clinic program
price object po base multipl ebitda
rel gener peer believ share trade similar
multipl gener peer lower closest peer teva latter
benefit low trough year uptick clinic de-risk spec brand
furthermor less visibl earn profil view
compani gener growth driver less durabl sourc growth teva key
spec brand believ dcf appropri valuat methodolog
littl visibl outlook beyond one two year multipl
take follow consider enjoy gener exclus
copaxon approv g-advair gener advair low-
mid-single-digit growth eu row busi
risk po approv g-advair greater-than-expect competit
pressur copaxon gener
price object po base blend averag dcf forward price-to-earnings po
impli stock trade ep current
multipl consensu ep multipl base
regress analysi histor us major pharma forward month price-to-earnings multipl
year forward compound-annual-growth-rate ep believ dcf analysi base reason
assumpt includ modest sale growth compound-annual-growth-rate
respect reflect loss exclus lyrica viagra collect
account us sale forecast near-term headwind
off-set key growth brand xeljanz ibranc xtandi flat
sale growth follow downward rebas us sale pipelin
overal sale forecast out-year sale dcf
assum wacc tgr
risk sale downsid us sale continu declin and/or competit
take meaning market share ibranc could lead downsid estim
po inabl grow busi in-lin forecast hold opex
spend flat level throughout forecast period transact
perceiv valu destruct dcf analysi reflect valu futur
 transact core element strategi
price object po base ev/ebitda multipl assum
teva trade ebitda multipl line peer
averag given low visibl teva busi beyond year
believ dcf analysi appropri valuat methodolog teva
ebitda multipl teva base compani ebitda growth outlook
base follow assumpt multipl copaxon gener
avail us gener base busi eros teva
largest gener product gener concerta declin
due increment competit sale new gener
product launch late
upsid risk failur copaxon gener gain approv
success teva secur meaning proce divestitur allergan work
capit disput could provid influx capit may allow teva reduc
leverag ratio strong new product launch
downsid risk success copaxon gener gain approv
failur teva secur meaning proce divestitur allergan work
capit disput could provid influx capit may allow teva reduc
leverag ratio weak new product launch
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
